Johnson & Johnson (NYSE: JNJ) released its second-quarter 2026 earnings report on Wednesday, posting both revenue and profit that exceeded Wall Street expectations. Yet the stock closed down nearly 3% on the day, standing in stark contrast to the broader market’s broad-based rally. Why did this “beat” fail to win over investors? What exactly is the market worried about?
A Beat, but a Modest One
The numbers show that J&J posted quarterly revenue of approximately $25.3 billion, up nearly 7% year-over-year and slightly above the analyst consensus of $25 billion. Adjusted net income came in at $7.08 billion, up about 6% year-over-year, or $2.90 per share, ahead of the $2.86 consensus estimate. Both key metrics beat expectations—but only marginally. In market parlance, this was merely a “soft beat.”
With investor expectations for large-cap pharmaceutical companies rising by the day, such a modest outperformance clearly failed to excite.
Innovative Medicine Carries the Load, Stelara’s Patent Cliff Continues to Bite
J&J’s business consists of two main segments: Innovative Medicine and MedTech. The Innovative Medicine segment generated nearly $16.4 billion in revenue during the quarter, up about 8% year-over-year, serving as the primary growth engine. Within this segment, immunology drug Tremfya was a standout performer, with sales surging 73% to $2 billion, rapidly filling the gap left by Stelara, whose sales plunged 56% (to $740 million) due to patent expiration. The oncology portfolio also remained robust, with flagship blood cancer treatment Darzalex posting a nearly 19% sales increase to over $4.2 billion, driving the entire oncology portfolio up 17% year-over-year to $7.4 billion.
MedTech revenue came in at roughly $8.9 billion, with growth of less than 5%—noticeably weaker than the pharmaceutical segment. The primary drag came from Abiomed and its Impella heart pump product line, which saw quarterly sales decline 2% to $440 million, a sharp reversal from the 16% growth recorded in the previous quarter. A U.K. study published in late March in the influential New England Journal of Medicine raised questions about Impella’s suitability and benefits for certain high-risk coronary interventions, fueling market concerns that physicians may alter their clinical choices—and J&J appears to have done little to allay those fears.
Guidance Raised, but the Market Wants More
Despite the quarterly blemishes, J&J still raised its full-year 2026 guidance: the company now expects revenue of $100.8 billion to $101.4 billion (up from the previous $100.3 billion to $101.3 billion), and adjusted earnings per share of $11.60 to $11.75 (up from $11.45 to $11.65). CEO Joaquin Duato said the quarter’s performance highlighted “the power of our innovation, the depth of our portfolio and the momentum in our pipeline.”
However, the market appears to have been hoping for a “blowout” beat rather than a modest raise. With competition among major pharmaceutical stocks intensifying, investors’ tolerance for missteps at J&J is narrowing.
The Bottom Line
J&J’s core competitive strengths—its oncology and immunology pipelines—remain solid, with Tremfya’s rise effectively offsetting the impact of Stelara’s patent cliff. However, the uncertainty surrounding Impella, the relatively subdued overall growth, and the only modest upward revision to full-year guidance together gave the market reason to “sell the news.” For long-term investors, the post-earnings pullback may offer a fresh entry point to re-evaluate the story—after all, for a healthcare giant with a 2.1% dividend yield and a valuation that has retreated from recent highs, the long-term value proposition has not been fundamentally altered by a single “not-quite-blowout” quarter.
